Our results indicated that the NCAPH2 methylation levels decreased during the SCD stage of the disease and reached a plateau at the cognitive impairment stage, suggesting that altered blood NCAPH2 methylation might be an early feature of AD pathology. This evidence concerns the gene NCAPH2 and Alzheimer disease.